Latent Tuberculosis Infection Resources

• Advisory Council for the Elimination of Tuberculosis (ACET): Roadmap for Advancing TB Elimination in the United States through Scale up of Testing and Treatment of Latent TB Infection pdf icon[PDF – 1 MB] (published in ACET Minutes of the Meeting June 16, 2020, Addendum 1, pages 40-51 pdf icon[PDF – 612KB])
  This statement from ACET updates the strategy to eliminate TB in the United States. The report provides new recommendations to prevent TB, specifically through focus on identifying individuals at risk and testing and treating latent TB infection.

• USPSTF Latent Tuberculosis Infection: Screening Recommendationexternal icon
  The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.

• • The Journal of the American Medical Association (JAMA)external iconThe Journal of the American Medical Association (JAMA)external icon

• • USPSTF LTBI Recommendation: Statement from Dr. Phillip LoBue, Director, CDC’s Division of Tuberculosis Elimination

• American Journal of Nursing: Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United Statesexternal icon
  This article provides an overview of tuberculosis transmission, pathogenesis, and epidemiology, presents preventive care recommendations for targeted testing among high-risk groups, and discusses the nursing implications of a new U.S. Preventive Services Task Force recommendation statement on latent tuberculosis infection testing.

• Interferon-Gamma Release Assays (IGRAs) – Blood Tests for TB Infection
  Interferon-Gamma Release Assays (IGRAs) are whole-blood tests that can aid in diagnosing Mycobacterium tuberculosis infection.
• Targeted Tuberculosis Testing and Interpreting Tuberculin Skin Test Results
  CDC and USPSTF recommend testing populations that are at increased risk for TB infection. Health care providers should consider several criteria when classifying positive TST reactions.

• Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020pdf icon
  These updated 2020 LTBI treatment guidelines include the NTCA- and CDC-recommended treatment regimens that comprise three preferred rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid.

• • Latent TB Infection Treatment Regimens – Treatment Tablepdf icon
  • Latent TB Infection Treatment – FAQ for Clinicians
  • Latent TB Infection Treatment – FAQ for Pharmacists
  • MMWR/Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.external icon
    Registration may be required.

• Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection
  CDC continues to recommend 3HP for treatment of LTBI in adults and now recommends use of 3HP 1) in persons with LTBI aged 2–17 years; 2) in persons with LTBI who have HIV infection, including acquired immunodeficiency syndrome (AIDS), and are taking antiretroviral medications with acceptable drug-drug interactions with rifapentine; and 3) by DOT or self-administered therapy (SAT) in persons aged ≥2 years.

• • The 12-Dose Regimen for Latent TB Infection Treatment: Fact Sheet for Clinicianspdf icon
  • Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Providers
  • Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Pharmacists
  • CDC Medscape Commentary: Latent TB Infection Updated Treatment Recommendationsexternal icon

• Treatment Options of Latent Tuberculosis Infection
  Available fact sheets on TB treatment include:

• • Information on Treatment for Latent TB Infection
  • 12-Dose Regimen for Latent TB Infection Treatment: Fact Sheet for Clinicians
  • Treatment of Latent Tuberculosis Infection: Maximizing Adherence

• Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIVexternal icon
  These guidelines are intended for clinicians, other health care providers, patients with HIV, and policy makers in the United States.

• Latent TB Infection Testing and Treatment: Summary of U.S. Recommendationspdf icon
  This summary includes information on testing for TB infection, recommended test for TB infection, and recommended treatment regimens for latent TB infection.
• Latent Tuberculosis Infection: A Guide for Primary Health Care Providers
  The guide includes latent TB infection diagnosis and treatment information, sample documentation forms, and additional resources.
• Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection (slide set)
  The slide set provides an overview of the current recommendations for the testing and treatment of latent tuberculosis. The target audience for this slide set is primary health care providers.
• CDC Messages and Resourcespdf icon
  This information may be helpful in communication activities to inform and educate partners, stakeholders, and media about the importance of expanded latent TB infection testing and treatment in eliminating TB in the United States.

• Testing for Tuberculosis
  This fact sheet provides information about the two kinds of tests that are used to determine if a person has been infected with TB bacteria: the tuberculin skin test and TB blood tests.
• Tuberculin Skin Testing
  The Mantoux tuberculin skin test is one method of determining whether a person is infected with Mycobacterium tuberculosis.

Information and tools for patients on latent TB treatment.

• 12-Dose Regimen for Latent TB Infectionpdf icon
  • Englishpdf icon
  • Chinesepdf icon
  • Haitian Creolepdf icon
  • Marshallesepdf icon
  • Spanishpdf icon
  • Tagalogpdf icon
  • Vietnamesepdf icon

• 12-Dose Regimen for Latent TB Infection-Medication Tracker and Symptom Checklistpdf icon
  • Englishpdf icon
  • Chinesepdf icon
  • Haitian Creolepdf icon
  • Marshallesepdf icon
  • Spanishpdf icon
  • Tagalogpdf icon
  • Vietnamesepdf icon

• 4 Months Daily Rifampin Schedule for Latent Tuberculosis (TB) Infectionpdf icon
• 3 Months of Daily Isoniazid plus Rifampin (3HR)pdf icon

These fact sheets will give an overview of regimens for latent TB infection and provide resources for patients.

• Isoniazid-specific regimenpdf icon
• Rifampin-specific regimenpdf icon
• What You Need to Know About Your Medicine for Latent Tuberculosis (TB) Infection – Isoniazid and Rifapentinepdf icon

• Questions and Answers about Tuberculosis
  Questions and Answers About Tuberculosis (TB) provides information on the diagnosis and treatment of TB infection and TB disease.

• Englishpdf icon
• Spanish
• Tagalogpdf icon
• Vietnamesepdf icon

• Slide Set—Introduction to Tuberculosis
  This slide set provides a basic overview of TB using plain language and visual aids.

• Kelcie’s Story of LTBI Testing and Treatment
  Like many people, Kelcie wasn’t familiar with latent TB infection and wasn’t sure what she should do about it.

• 5 Things to Know about TBexternal icon
  This video highlights the continuing problem of tuberculosis (TB) in the United States.